Heart Failure Hemodynamics: Fick-Derived Parameters, Forrester Profiles, and Hemodynamic-Guided Therapy

Heart failure hemodynamics are characterized by two principal abnormalities: elevated filling pressures (congestion) and reduced cardiac output (hypoperfusion). These two dimensions can be assessed clinically and confirmed invasively during right heart catheterization. The pulmonary capillary wedge pressure (PCWP) serves as the standard marker of left-sided filling pressures, with values above 18 mmHg indicating clinically significant congestion. The cardiac index (CI), calculated by dividing Fick cardiac output by body surface area, quantifies systemic perfusion, with values below 2.2 L/min/m² defining inadequate forward output.

In heart failure with reduced ejection fraction (HFrEF), the hemodynamic profile typically includes elevated PCWP, reduced CI, elevated systemic vascular resistance (SVR) due to neurohormonal activation, and elevated right atrial pressure when biventricular failure is present. Heart failure with preserved ejection fraction (HFpEF) presents a more complex hemodynamic phenotype: resting PCWP may be normal or only mildly elevated, but it rises disproportionately with exercise or volume loading due to impaired ventricular compliance and diastolic dysfunction. Exercise hemodynamics — measuring PCWP during supine bicycle ergometry in the catheterization laboratory — are increasingly used to unmask HFpEF when resting hemodynamics are equivocal.

Right heart failure adds another hemodynamic dimension characterized by elevated right atrial pressure (RAP > 12 mmHg), reduced right ventricular stroke work index, and disproportionate RV dilation relative to the left ventricle. The ratio of RAP to PCWP provides insight into the relative contribution of right versus left heart dysfunction: an RAP/PCWP ratio greater than 0.63 suggests predominant right heart failure and is associated with worse prognosis. Hemodynamic assessment with the PA catheter is the only method that simultaneously quantifies both right and left heart function, making it indispensable in complex heart failure phenotyping.

The Forrester classification, introduced by James Forrester and colleagues in 1976, divides patients with acute myocardial infarction (and subsequently all heart failure patients) into four hemodynamic subsets based on cardiac index and PCWP measured during right heart catheterization. The two axes — CI above or below 2.2 L/min/m² and PCWP above or below 18 mmHg — create a 2×2 matrix that assigns patients to profiles with distinct clinical presentations, treatment strategies, and prognostic implications. This classification remains one of the most widely used frameworks in acute and advanced heart failure management.

Forrester Profile I (warm and dry: CI ≥ 2.2, PCWP ≤ 18) represents compensated hemodynamics with adequate perfusion and no significant congestion. Profile II (warm and wet: CI ≥ 2.2, PCWP > 18) is the most common presentation in acute decompensated heart failure, with preserved perfusion but elevated filling pressures manifesting as dyspnea and peripheral edema; treatment focuses on diuresis and afterload reduction. Profile III (cold and dry: CI < 2.2, PCWP ≤ 18) indicates low output without overt congestion, often seen in over-diuresed patients or those with predominant right heart failure; treatment requires cautious volume expansion or inotropic support.

Forrester Profile IV (cold and wet: CI < 2.2, PCWP > 18) represents the most severe hemodynamic derangement with both congestion and hypoperfusion, corresponding to cardiogenic shock. Patients in Profile IV have the highest mortality and require aggressive hemodynamic optimization with intravenous vasodilators, inotropes, vasopressors, and potentially mechanical circulatory support (intra-aortic balloon pump, Impella, or extracorporeal membrane oxygenation). The bedside clinical assessment of warm/cold (perfusion) and wet/dry (congestion) by physical examination has moderate concordance with invasive hemodynamics, but up to 25% of patients may be misclassified without catheterization data, particularly in chronic heart failure where physical signs become attenuated.

The Fick cardiac output is particularly valuable in heart failure because thermodilution becomes progressively less accurate as cardiac output declines below 3.5 L/min, with thermodilution tending to overestimate output in low-flow states due to heat loss along the catheter and indicator recirculation. In patients with severe tricuspid regurgitation — common in advanced right heart failure — thermodilution may significantly underestimate forward cardiac output because the regurgitant volume distorts the thermodilution curve. The Fick method, which relies on metabolic oxygen consumption and arteriovenous oxygen difference, remains accurate regardless of tricuspid regurgitation or low-flow conditions, making it the preferred technique in heart failure populations.

Mixed venous oxygen saturation (SvO₂), obtained from the PA catheter, is a powerful global indicator of hemodynamic adequacy in heart failure. A normal SvO₂ of 60–80% reflects an appropriate balance between oxygen delivery (dependent on CO, Hb, and SaO₂) and oxygen consumption (VO₂). An SvO₂ below 60% indicates increased oxygen extraction due to inadequate delivery, which in the heart failure context typically reflects low cardiac output. An SvO₂ below 40% is associated with tissue hypoxia and anaerobic metabolism, and values below 30% predict poor survival without escalation of therapy. Continuous SvO₂ monitoring via fiber-optic PA catheters allows real-time tracking of hemodynamic adequacy during inotrope or vasodilator titration.

The cardiac power output (CPO), calculated as MAP × CO / 451, is the strongest independent hemodynamic predictor of in-hospital mortality in cardiogenic shock. A CPO less than 0.6 watts identifies patients at highest risk who may benefit from early mechanical circulatory support. The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) classification further stratifies advanced heart failure patients into seven profiles based on clinical severity, ranging from Profile 1 (critical cardiogenic shock with escalating vasopressor and inotrope requirements) to Profile 7 (advanced NYHA Class III symptoms). Fick-derived hemodynamic data, including CI, PCWP, and PVR, are integral to the INTERMACS evaluation and to determining candidacy for durable mechanical circulatory support or transplantation.

Hemodynamic-guided therapy in heart failure uses serial PA catheter measurements to titrate medications toward predefined targets: PCWP ≤ 15 mmHg, RAP ≤ 8 mmHg, SVR 800–1200 dyn·s·cm⁻⁵, and CI ≥ 2.2 L/min/m². In the ESCAPE trial, patients randomized to PAC-guided therapy achieved greater hemodynamic improvement and more days alive out of hospital, though no overall survival benefit was demonstrated. Current guidelines (ACC/AHA Class IIa) recommend PAC use when hemodynamic data are needed to guide management in patients with cardiogenic shock, refractory heart failure, or uncertain hemodynamic status despite appropriate empiric therapy.

In practice, the hemodynamic response to specific interventions is monitored sequentially: intravenous loop diuretics reduce PCWP and RAP; nitroprusside or nesiritide reduces SVR and PCWP while increasing CI; milrinone and dobutamine increase CI while reducing filling pressures; and norepinephrine or vasopressin restore MAP in vasodilatory shock. The ability to measure the immediate hemodynamic effect of each intervention and adjust doses accordingly is the principal advantage of PA catheter monitoring. When PCWP and CI targets cannot be achieved with pharmacological therapy alone, escalation to temporary mechanical circulatory support (e.g., Impella, IABP) should be considered, with the PAC serving as the monitoring tool to assess device efficacy.